Investigating the role of stathmin-2 in neurological disorders linked to TDP-43 protein abnormalities
In vivo modelling and therapy development for stathmin-2 loss in TDP-43 proteinopathies
This study is looking at how a protein called stathmin-2, which helps nerve cells grow and heal, is linked to conditions like ALS and frontotemporal dementia, with the hope of finding new treatments that can help improve nerve repair for people dealing with these challenges.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10795741 on NIH RePORTER |
What this research studies
This research focuses on understanding how the loss of stathmin-2, a protein crucial for nerve cell growth and repair, is connected to neurological disorders like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). By using advanced mouse models, the team aims to explore the mechanisms behind TDP-43 proteinopathies, which involve the misplacement of the TDP-43 protein in nerve cells. The goal is to develop therapies that could restore stathmin-2 levels and improve nerve regeneration in affected patients. This research could lead to new treatment strategies for patients suffering from these debilitating conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with amyotrophic lateral sclerosis, frontotemporal dementia, or Alzheimer's disease, particularly those showing signs of TDP-43 pathology.
Not a fit: Patients with neurological disorders not associated with TDP-43 protein abnormalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that enhance nerve regeneration and improve outcomes for patients with ALS, FTD, and Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in targeting stathmin-2 for therapeutic purposes in related neurological conditions, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Lagier-Tourenne, Clotilde — Massachusetts General Hospital
- Study coordinator: Lagier-Tourenne, Clotilde
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.